ERBB2 and breast cancer: Publicly available summary-level Breast Cancer Association Consortium data (n = 247,173; 133,384 cases, 113,789 controls) for the following subtypes were included: luminal A–like (45,253 cases), luminal B–/HER2-negative–like (6,350 cases), luminal B–like (6,427 cases), HER2-enriched (2,884 cases), and triple-negative (8,602 cases).